

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q75926

Ryuichi MORISHITA, et al.

1.53(b) Divisional Appln. of
Application No: 09/660,522

Confirmation No.: Not yet assigned

Group Art Unit: 1636 (prior application)

Filed: July 9, 2003

Examiner: D. Lambertson (prior application)

For: **MEDICAMENT COMPRISING HGF GENE**

PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SUBSTITUTE SPECIFICATION:

Amend the substitute specification by inserting before the first line the sentence:

--This is a divisional of Application No. 09/660,522, filed September 12, 2000, which is a continuation of Application No. 09/029,497 filed February 26, 1998; which is a 371 National Stage Application of PCT/JP96/02359 filed August 22, 1996, the disclosures of which are incorporated herein by reference.--

Please amend paragraph 27, bridging pages 7 and 8 as follows:

Where the HGF gene is introduced into, e.g., cells, the growth of vascular endothelial cells is accelerated, while undesired growth of vascular smooth muscle cells is not accelerated, as demonstrated in the Examples hereinafter. Moreover, as demonstrated in the Examples